公开(公告)号：US12122827B2

公开(公告)日：2024-10-22

申请号：US18307477

申请日：2023-04-26

Applicant: Asher Biotherapeutics, Inc.

Inventor： Yik Andy Yeung ,  Renee L. Greer ,  Henry C. Nguyen ,  David Liu ,  Byong Kang ,  Ivana Djuretic

IPC: C07K16/24 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/244 ,  A61P35/00 ,  C07K14/54 ,  C07K16/2815 ,  C07K16/40 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/74

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

公开(公告)号：US20250034242A1

公开(公告)日：2025-01-30

申请号：US18915009

申请日：2024-10-14

Applicant: Asher Biotherapeutics, Inc.

Inventor： Yik Andy Yeung ,  Renee L. Greer ,  Henry C. Nguyen ,  David Liu ,  Byong Kang ,  Ivana Djuretic

IPC: C07K16/24 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  C07K16/40

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

公开(公告)号：US20230357343A1

公开(公告)日：2023-11-09

申请号：US18307477

申请日：2023-04-26

Applicant: Asher Biotherapeutics, Inc.

Inventor： Yik Andy Yeung ,  Renee L. Greer ,  Henry C. Nguyen ,  David Liu ,  Byong Kang ,  Ivana Djuretic

IPC: C07K14/54 ,  C07K16/40 ,  C07K16/28 ,  A61P35/00

CPC classification number: C07K14/54 ,  C07K16/40 ,  C07K16/2815 ,  A61P35/00 ,  C07K2319/33 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2319/30 ,  A61K2039/505

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

公开(公告)号：US20230340104A1

公开(公告)日：2023-10-26

申请号：US18308338

申请日：2023-04-27

Applicant: Asher Biotherapeutics, Inc.

Inventor： Yik Andy Yeung ,  Renee L. Greer ,  Henry C. Nguyen ,  David Liu ,  Byong Kang ,  Ivana Djuretic

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2319/74 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/64

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.